TheEdgeResearch
Home / Stocks / REPCF

RepliCel Life Sciences Inc. (REPCF)

OTC Healthcare Biotechnology
$0.00 ▲ +0.00%
Market Cap
$7,357
Sector
Healthcare
Industry
Biotechnology
Beta
0.56
52-Wk Range
0.00001-0.042835
CEO
Andrew Schutte
Country
CA
Currency
USD

RepliCel Life Sciences Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Vancouver, BC, CA. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $7,357. On trailing twelve-month figures it carries a trailing P/E of -9.38, a net margin of -27.5%. Its beta of 0.56 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-9.38
Price / Sales
3.12
Price / Book
-0.21
EV / EBITDA
-5.33
Gross margin
100.0%
Operating margin
-101.8%
Net margin
-27.5%
Return on equity
—
Debt / equity
-0.19
Current ratio
0.09
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
1
IPO date
2010-05-03
Headquarters
Vancouver, BC, CA
About RepliCel Life Sciences Inc.

Headquartered in Vancouver, Canada, RepliCel Life Sciences Inc. is a regenerative medicine company dedicated to developing innovative autologous cell therapies. These treatments are designed to correct functional cellular deficiencies by harnessing a patient's own cells. The process involves isolating cells from harvested tissues, significantly expanding them in a controlled laboratory environment, and subsequently applying them therapeutically. The company's developmental portfolio includes several key product candidates: RCT-01 targets chronic tendinosis, RCS-01 addresses aging and sun-damaged skin, and RCH-01 is aimed at treating hair loss. Additionally, RepliCel is advancing RCI-02, a specialized dermal injection device. RepliCel has established significant strategic alliances. It holds a collaboration and technology transfer agreement with YOFOTO (China) Health Industry Co. Ltd. to establish a clinical research program and facilitate the commercialization of RCS-01 and RCT-01. A similar collaboration exists with Shiseido Company, Limited, focusing on the clinical research program for RCH-01. Furthermore, the company is engaged in a research project agreement with the University of British Columbia, contributing to the creation of a comprehensive hair follicle cell data map.

Comparable companies

RepliCel Life Sciences Inc. is most often compared with the following Healthcare names:

CVMEXELINCYJAGXPKTXREPLRGRXRVXCFSRBCF
More research on REPCF
REPCF technical analysis REPCF TheEdge Score Compare against peers
Open full interactive analysis & DCF →